Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day.
What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?
Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ...
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.
The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program.
This agreement produced a license for a UHN technology on April 17, 2013.